Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy

被引：0
|
作者：
Ungaro, Ryan [1 ]
Jossen, Jacqueline [1 ]
Phan, Becky [2 ]
Chefitz, Ezra
Jain, Anjali [1 ,3 ]
Naik, Snehal [3 ]
Dubinsky, Marla [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Div Pediat Gastroenterol & Hepatol, New York, NY 10029 USA
[3] Prometheus Labs Inc, San Diego, CA USA
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PD-006
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [1] HIGHER VEDOLIZUMAB TROUGH LEVELS ASSOCIATED WITH REMISSION IN INFLAMMATORY BOWEL DISEASE (IBD) DURING MAINTENANCE THERAPY
    Ungaro, Ryan C.
    Jossen, Jacqueline
    Phan, Becky L.
    Chefitz, Ezra
    Sehgal, Priya
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    GASTROENTEROLOGY, 2017, 152 (05) : S384 - S385
  • [2] Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease
    Ungaro, Ryan C.
    Yarur, Andres
    Jossen, Jacqueline
    Phan, Becky L.
    Chefitz, Ezra
    Sehgal, Priya
    Kamal, Kanika
    Bruss, Alexandra
    Beniwal-Patel, Poonam
    Fox, Caroline
    Patel, Amir
    Bahur, Bayda
    Jain, Anjali
    Stein, Daniel
    Naik, Snehal
    Dubinsky, Marla C.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (08): : 963 - 969
  • [3] Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease
    Ritter, Einat
    Hirsch, Ayal
    Isakov, Naomi F.
    Ron, Yulia
    Cohen, Nathaniel A.
    Maharshak, Nitsan
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (09) : 810 - 814
  • [4] Vedolizumab Drug Levels During Maintenance Therapy in Inflammatory Bowel Disease Patients
    Koduru, Pramoda
    Morrill, Amanda
    Abraham, Bincy
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S63 - S64
  • [5] Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
    Liefferinckx, Claire
    Minsart, Charlotte
    Cremer, Anneline
    Amininejad, Leila
    Tafciu, Vjola
    Quertinmont, Eric
    Tops, Sophie
    Deviere, Jacques
    Gils, Ann
    van Gossum, Andre
    Franchimont, Denis
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (04) : 478 - 485
  • [6] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [7] Vedolizumab Levels During Induction Are Associated With Remission in Patients With Inflammatory Bowel Diseases
    Yarur, Andres
    Bruss, Alexandra
    Patel, Amir
    Beniwal-Patel, Poonam
    Fox, Caroline
    Ungaro, Ryan
    Dubinsky, Marla C.
    Naik, Snehal
    Stein, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S353 - S354
  • [8] Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
    Yarur, A.
    Bruss, A.
    Jain, A.
    Kondragunta, V.
    Hester, K.
    Luna, T.
    Agrawal, D.
    Patel, A.
    Fox, C.
    Werner, S.
    Naik, S.
    Stein, D.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S38 - S38
  • [9] HIGHER VEDOLIZUMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS ON MAINTENANCE THERAPY WITH VEDOLIZUMAB
    Yarur, Andres J.
    Bruss, Alexandra
    Jain, Anjali
    Kondragunta, Venkateswarlu
    Luna, Theresa L.
    Hester, Kelly
    Patel, Amir
    Agrawal, Dilpesh
    Fox, Caroline
    Werner, Shannon
    Naik, Snehal
    Stein, Daniel J.
    GASTROENTEROLOGY, 2017, 152 (05) : S389 - S389
  • [10] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
12345